Lisata Therapeutics Inc (LSTA)

[whirlybird]

Need for financing is obvious, BUT --

Although I suspect it would cost less than 50 million to complete an AMR P3 study, perhaps 25 - 30 million, there is still the meta-t P3 study costing an estimated 25 million and a host of other studies pending. Total financing needs could be approaching 75 million and more. The desperate need for financing is obvious.

Management is not suicidal. That is why a partnership or buyout is likely in the immediate future. Either could be with BAX that is finishing their P3 RESERVE study around June, coincidentally about the same time as the P2 AMR study. BAX could spend as much for COGs using the PCT stem cells in their study as it would cost to initiate a buyout or BAX may elect for a partnership.

Obviously, there are other possibilities including interest from other major pharmaceuticals emerging.

Keep in mind too that Cardio3 Biosciences is finishing a P3 study using PCT stem cells in Europe and CBMG is finishing a P2b study using California Stem Cell technology. More than a dozen studies of various sorts are being done with PCT or CSC technology.

Remember too the Gamida Cell precedent just a month ago of a buyout offer probably in the hundreds of millions of dollars. Many major pharmaceuticals want a stem cell presence.